Literature DB >> 10507763

The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells.

D Trerè1, L Fiume, L B De Giorgi, G Di Stefano, M Migaldi, M Derenzini.   

Abstract

The expression of the asialoglycoprotein receptor (ASGP-R) on human hepatocellular carcinoma (HCC) cells might be exploited to reduce the extrahepatic toxicity of DNA synthesis inhibitors by their conjugation with galactosyl-terminating peptides. In the present study we first assessed the frequency of ASGP-R expression in 60 HCCs. Secondly, we investigated whether the receptor was maintained on the plasma membranes of DNA synthesizing cancer cells. Needle biopsies of HCC were evaluated. Diagnosis and grading of HCC were performed on routine haematoxylin and eosin-stained sections according to Edmondson and Steiner (1953). Thirty-five tumours were grade I and II and were classified as well differentiated, while 25 tumours were grade III and IV and were classified as poorly differentiated. Sections from formalin-fixed, paraffin-embedded samples were incubated, after antigen retrieval, with an anti-ASGP-R monoclonal antibody revealed by secondary biotinylated antibody and streptavidin-biotin-peroxidase-diaminobenzidine reaction. A clear immunolabelling of plasma membranes of HCC cells was observed in 28 out of 35 (80%) well differentiated (grade I and II) and in five out of 25 (20%) poorly differentiated (grade III and IV) HCCs. The presence of the ASGP-R on the surface of DNA synthesizing cancer cells was also investigated after in vitro bromodeoxyuridine (BrdU) labelling of HCC samples by immunohistochemical visualization of both the ASGP-R and incorporated BrdU on the same section. The results obtained clearly demonstrated that DNA synthesizing cancer cells expressed the ASGP-R on their surface. The presence of ASGP-R on cell plasma membrane in the majority of differentiated HCCs and its maintenance on proliferating cells encourages studies in order to restrict the action of the inhibitors of DNA synthesis of HCC cells by their conjugation with galactosyl-terminating carriers internalized through this receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507763      PMCID: PMC2362929          DOI: 10.1038/sj.bjc.6690708

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo.

Authors:  A G Morell; R A Irvine; I Sternlieb; I H Scheinberg; G Ashwell
Journal:  J Biol Chem       Date:  1968-01-10       Impact factor: 5.157

3.  Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin.

Authors:  L Fiume; A Mattioli; P G Balboni; M Tognon; G Barbanti-Brodano; J de Vries; T Wieland
Journal:  FEBS Lett       Date:  1979-07-01       Impact factor: 4.124

4.  Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects.

Authors:  M Torrani Cerenzia; L Fiume; W De Bernardi Venon; B Lavezzo; M R Brunetto; A Ponzetto; G Di Stefano; C Busi; A Mattioli; G B Gervasi; F Bonino; G Verme
Journal:  Hepatology       Date:  1996-04       Impact factor: 17.425

5.  Effect of galactose on interaction of N-(2-hydroxypropyl)methacrylamide copolymers with hepatoma cells in culture: preliminary application to an anticancer agent, daunomycin.

Authors:  K B O'Hare; I C Hume; L Scarlett; V Chytrý; P Kopecková; J Kopecek; R Duncan
Journal:  Hepatology       Date:  1989-08       Impact factor: 17.425

6.  Production and characterization of specific asialoglycoprotein receptor antibodies.

Authors:  Y Kohgo; J Kato; R Nakaya; Y Mogi; H Yago; Y Sakai; H Matsushita; Y Niitsu
Journal:  Hybridoma       Date:  1993-10

7.  AgNOR area in interphase nuclei of human tumours correlates with the proliferative activity evaluated by bromodeoxyuridine labelling and Ki-67 immunostaining.

Authors:  D Trerè; F Farabegoli; A Cancellieri; C Ceccarelli; V Eusebi; M Derenzini
Journal:  J Pathol       Date:  1991-09       Impact factor: 7.996

8.  Hyperasialoglycoproteinemia in patients with chronic liver diseases and/or liver cell carcinoma. Asialoglycoprotein receptor in cirrhosis and liver cell carcinoma.

Authors:  T Sawamura; H Nakada; H Hazama; Y Shiozaki; Y Sameshima; Y Tashiro
Journal:  Gastroenterology       Date:  1984-12       Impact factor: 22.682

9.  Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma.

Authors:  I Hyodo; M Mizuno; G Yamada; T Tsuji
Journal:  Liver       Date:  1993-04

10.  Characterization of the asialoglycoprotein receptor in a continuous hepatoma line.

Authors:  A L Schwartz; S E Fridovich; B B Knowles; H F Lodish
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

View more
  16 in total

1.  Establishment of a functional cell line expressing both subunits of H1a and H2c of human hepatocyte surface molecule ASGPR.

Authors:  Bin Hu; Yan Yang; Jia Liu; Zhiyong Ma; Hongping Huang; Shenpei Liu; Yuan Yu; Youhua Hao; Baoju Wang; Mengji Lu; Dongliang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

2.  Constant serum levels of secreted asialoglycoprotein receptor sH2a and decrease with cirrhosis.

Authors:  Ron Benyair; Maria Kondratyev; Elena Veselkin; Sandra Tolchinsky; Marina Shenkman; Yoav Lurie; Gerardo Z Lederkremer
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

3.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

4.  Improved method increases sensitivity for circulating hepatocellular carcinoma cells.

Authors:  Hui-Ying Liu; Hai-Hua Qian; Xiao-Feng Zhang; Jun Li; Xia Yang; Bin Sun; Jun-Yong Ma; Lei Chen; Zheng-Feng Yin
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 5.  A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.

Authors:  Samaresh Sau; Katyayani Tatiparti; Hashem O Alsaab; Sushil K Kashaw; Arun K Iyer
Journal:  Drug Discov Today       Date:  2018-03-15       Impact factor: 7.851

6.  Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma.

Authors:  Bin Shi; Marc Abrams; Laura Sepp-Lorenzino
Journal:  J Histochem Cytochem       Date:  2013-08-26       Impact factor: 2.479

7.  Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4.

Authors:  Bo Lian; Hua Wei; Ruiyan Pan; Jingui Sun; Bo Zhang; Jingliang Wu; Xiujie Li; Guixiang Tian
Journal:  Int J Nanomedicine       Date:  2021-01-15

8.  A secreted form of the asialoglycoprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosis.

Authors:  Elena Veselkin; Maria Kondratyev; Yoav Lurie; Efrat Ron; Moshe Santo; Shimon Reif; Irma Elashvili; Lana Bar; Gerardo Z Lederkremer
Journal:  PLoS One       Date:  2011-11-11       Impact factor: 3.240

9.  Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma.

Authors:  Wan-Jiang Xue; Ying Feng; Fei Wang; Yi-Bing Guo; Peng Li; Lei Wang; Yi-Fei Liu; Zhi-Wei Wang; Yu-Min Yang; Qin-Sheng Mao
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

10.  Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.

Authors:  Jennifer L S Willoughby; Amy Chan; Alfica Sehgal; James S Butler; Jayaprakash K Nair; Tim Racie; Svetlana Shulga-Morskaya; Tuyen Nguyen; Kun Qian; Kristina Yucius; Klaus Charisse; Theo J C van Berkel; Muthiah Manoharan; Kallanthottathil G Rajeev; Martin A Maier; Vasant Jadhav; Tracy S Zimmermann
Journal:  Mol Ther       Date:  2017-09-07       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.